Information Provided By: 
Fly News Breaks for November 22, 2017
OSUR
Nov 22, 2017 | 07:36 EDT
Canaccord analyst Mark Massaro noted OraSure won a massive $143M contract to supply its market-leading Oragene Dx saliva collection device to a leading generics customer. The analyst said the contract win is bigger than its previous year revenue number and indicates the direct-to-consumer genomics business is booming. Massaro reiterated his Buy rating and raised his price target to $21 from $19 on OraSure shares.
News For OSUR From the Last 2 Days
There are no results for your query OSUR
